- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03587038
OKN-007 in combinatie met adjuvante temozolomide-chemoradiotherapie voor pas gediagnosticeerd glioblastoom
Haalbaarheid Pilotstudie van OKN-007 in combinatie met adjuvante temozolomide-chemoradiotherapie bij patiënten met nieuw gediagnosticeerd glioblastoom
This is a pilot study exploring the potential benefit of adding OKN-007 with Temozolomide for treatment in patients with malignant Glioblastoma undergoing adjuvant concomitant radiotherapy. This drug combination is expected to have an anti-cancer effect in patients who have experienced disease progression after first line treatment.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Verenigde Staten, 73117
- Stephenson Cancer Center, University of Oklahoma Health Sciences Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Patients have newly diagnosed histologically proven WHO grade III or grade IV Glioblastoma Multiforme (GBM).
- Patients at initial presentation of GBM must undergo an adequate surgical resection of the primary lesion; patients must be registered within 49 days (7 weeks) of the surgery.
- Patients must have available and be willing to submit a minimum of five unstained slides tumor tissue specimens from the GBM surgery or open biopsy for MGMT status analysis and molecular profile analysis.
- ECOG performance status within 0 - 2
- Full recovery (< grade 1) from the adverse events associated with prior surgery or any earlier intervention and a minimum of 28 days from the administration of any investigational agent
- Adequate renal, liver and bone marrow function: Leukocytes >3,000/mcL; Absolute neutrophil count >1,500/mcL; Platelets >100,000/mcL; AST / ALT (SGPT) <2.5 x ULN; Total bilirubin ≤ 1.5 x institutional upper limit of normal (IULN) (except Gilbert's Syndrome, who must have a total bilirubin < 3.0 mg/dL); Creatinine within normal limits
- Patients must be ≥ 18 years of age
- Patients must be willing to have blood draws for PK analysis
- All patients must have a CT or MRI of the brain within 14 days prior to registration. The brain CT or MRI should be performed with intravenous contrast (unless contraindicated).
- Patients must be informed of the investigational nature of this study and must sign and give written informed consent for this protocol in accordance with institutional and federal guidelines.
- Life expectancy ≥ 3 months, allowing adequate follow up of toxicity evaluation and progression-free survival evaluation;
- Female patient, if of childbearing potential, has a negative serum pregnancy test within 72 hours of taking study medication and agrees to abstain from activities that could result in pregnancy from enrollment through 120 days after the last dose of study treatment
- Male patient agrees to use an adequate method of contraception
- Birth control should be used from the signing of the patient consent form and for 120 days following the last dose of study treatment.
- In addition, men must not donate sperm during study therapy and for 120 days after receiving the last dose of study treatment.
Exclusion Criteria:
- Second primary malignancy (except adequately treated basal cell carcinoma of the skin).
- Patients who had another malignancy in the past, but have been free of active disease for more than 2 years, are eligible
- Have received treatment within the last 28 days with a drug that has not received regulatory approval for any indication at the time of study entry
- Serious concomitant systemic disorders (for example, active infection or abnormal electrocardiogram (ECG) indicative of cardiac disease) that, in the opinion of the investigator, would compromise the safety of the patient and his/her ability to complete the study
- Patients with moderate or severe renal impairment (calculated creatinine clearance of < 60 mL/min)
- Patients with sodium, potassium, or creatinine serum electrolytes > grade 2.
- Screening ECG abnormality documented by the investigator as medically significant
- Inability to comply with protocol or study procedures.
- Women who are pregnant or breastfeeding.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: OKN-007 3 days per week plus temozolomide
OKN-007: 60 mg/kg, IV, 3 times a week Temozolomide: 75 mg/m2, oral, once daily for 42 days Radiotherapy: 60 Gy administered in 30 fractions |
400 mg OKN-007/mL in a phosphate buffer 75 mg/m2 standard of care treatment to be given 1 to 2 hours after OKN-007 |
|
Experimenteel: OKN-007 5 days per week and temozolomide
OKN-007: 60 mg/kg, IV, 5 times a week Temozolomide: 75 mg/m2, oral, once daily for 42 days Radiotherapy: 60 Gy administered in 30 fractions |
400 mg OKN-007/mL in a phosphate buffer 75 mg/m2 standard of care treatment to be given 1 to 2 hours after OKN-007 |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
The maximum tolerated dose and the type of dose limiting toxicities
Tijdsspanne: 5 years
|
To determine how well patients are able to tolerate combination of OKN-007, temozolomide, and radiotherapy. Adverse events will be tabulated using MedDRA. The severity of the AE will be graded by the Investigator using the NCI CTCAE, version 4.03. |
5 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of participants who experience progression-free survival
Tijdsspanne: 5 years
|
To evaluate the proportion of patients who receive combination OKN-007 and TMZ who do not experience progression |
5 years
|
|
Number of participants who comply with study treatment plan
Tijdsspanne: 5 years
|
To evaluate the clinical compliance of participants receiving combination OKN-007 and TMZ |
5 years
|
|
Number of participants who are able to receive a reduction in steroid dose
Tijdsspanne: 5 years
|
To evaluate whether study drug combination allows for a reduced steroid dosage |
5 years
|
|
Number of participants who experience overall survival
Tijdsspanne: 5 years
|
To evaluate the proportion of patients who receive combination OKN-007 and TMZ who experience overall survival |
5 years
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: James Battiste, MD, Principal Investigator
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata
- Neoplasmata per histologisch type
- Neoplasmata, glandulair en epitheel
- Astrocytoom
- Glioom
- Neoplasmata, neuro-epitheliaal
- Neuro-ectodermale tumoren
- Neoplasmata, kiemcellen en embryonaal
- Neoplasmata, zenuwweefsel
- Glioblastoom
- Organische chemicaliën
- Heterocyclische verbindingen, 1-ring
- Heterocyclische verbindingen
- Azoles
- Fysieke fenomeen
- Dacarbazine
- Triazenen
- Imidazolen
- Elektromagnetische fenomenen
- Magnetische fenomenen
- Elektromagnetische straling
- Bestraling
- Elementaire deeltjes
- Licht
- Optische fenomenen
- Straling, niet -ionisatie
- Temozolomide
- Fotonen
- OKN 007
Andere studie-ID-nummers
- OU-SCC-Oblato-001
- OKN-007 (Ander subsidie-/financieringsnummer: Oblato Inc)
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .